ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other businesses that have established lifelong customers. Motley Fool analyst Bill Barker and host Dylan Lewis discuss: How weight loss drugs like Eli Lilly 's Zepbound might be coming for ResMed and the sleep apnea market.
RXO takes a bigger piece of the brokered transportation market, scooping up Coyote Logistics from UPS . Target and Shopify linking up for a win-win partnership. Motley Fool analyst Tim Beyers and host Ricky Mulvey discuss the value of lifetime customer relationships, why they're huge for the likes of Apple and Costco , and one lesser-known name that may have one too.
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center . To get started investing, check out our quick-start guide to investing in stocks . A full transcript follows the video.
This video was recorded on June 24, 2024. Dylan Lewis: Weight loss drugs Zepbound and Mounjaro are putting other markets on notice. Motley Fool Money starts now.
I'm Dylan Lewis, and I'm joining over the airwaves by Motley Fool analyst, Bill Barker. Bill, thanks for joining me. Bill Barker: Thanks for having me.
Dylan Lewis: We've got Shopify striking a valuable partnership, a look at businesses that create customers for life. We're going to kick off today talking about one of the topics for 2024.